Dr. Charles Keller, Scientific Director, Children's Cancer Therapy Development Institute is working with a diverse team in this non-profit biotech to make all childhood cancers universally survivable. Filling the preclinical gap, cc-TDI is moving drugs for pediatric brain tumors and muscle cancers into national clinical trials. Charles also sheds light on the incentives and obligations legislated in the Creating Hope Act that insures childhood cancers though rare, are given the same consideration for study as adult cancers.
@cctdilab #childhoodcancer #pediatriccancer #cancer #braintumor
cc-TDI.org
Download the transcript here
Empowered Patient Podcast